Preet M Chaudhary, MD, PhD

Professor of Medicine

Bloom Family Chair in Lymphoma Research

Chief, Nohl Division of Hematology and Center for Blood Diseases in the Department of Medicine

Director for Bone Marrow Transplant

Image of Preet M Chaudhary, MD, PhD
Is this your profile? Click to edit

Overview

Preet M. Chaudhary, M.D., Ph.D. is chief of the Jane Anne Nohl Division of Hematology and Center for the study of Blood Diseases in the Department of Medicine, and coleader of the Molecular Genetics Program at the USC Norris Comprehensive Cancer Center. He is also Professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and Program Director of the USC/Norris Blood and Marrow Transplant Program.

As a physician-scientist dedicated to hematologic oncology, Dr. Chaudhary has research interests in several areas of cancer, including AIDS-associated cancers, cancer drug resistance, biology of normal and leukemic hematopoietic stem cells, programmed cell death and cellular signaling. He is also interested in molecularly targeted and cellular therapies for leukemias, lymphomas, multiple myeloma and solid tumors. Current work in Dr. Chaudhary’s laboratory is focused on developing novel strategies to improve the outcome of stem cell transplantation and the use of chimeric antigen receptor modified T cells for the treatment of cancer.

Dr. Chaudhary holds six U.S. patents and has published in some of the top scientific journals, including Cell, Immunity, JNCI, PNAS and Blood. He has served as a peer-reviewer for several national and international cancer research funding agencies and has been elected to the prestigious American Society for Clinical Investigations, an honor society of the top physician-scientists in the country.

Awards

  • Leukemia Lymphoma Society: Translational Research Award, 2005
     – 2008
  • Leukemia Lymphoma Society: Translational Research Award, 2008
     – 2011
  • Multiple Myeloma Research Foundation: Senior Research Award, 2005
     – 2006
  • American Society for Clinical Investigations, 2004
  • Leukemia Research Foundation: New Investigator Award, 1999
     – 2000
  • Howard Hughes Institutes: New Faculty Start-Up Award, 1998
     – 2001
  • Damon Runyon-Walter Winchell Foundation: Postdoctoral Fellowship, 1995
     – 1998
  • March of Dimes Birth Defects Foundation: Pre-doctoral Fellowship, 1990
     – 1992
  • Second Prize in Ophthalmology, 1986
  • Gold Medal in Surgery, 1986
  • Second Prize in Pathology, 1985
  • 1984
     -: Distinctions in Anatomy, Physiology Biochemistry and Pharmacology, 1984
     – 1985
  • Honors in First Professional M.B.B.S, 1984
  • Pre-Medical University Merit Certificate (First Rank in the College), 1981
  • 1981
     -: National Talent Search Scholarship, 1981
     – 1986

Research Funding

  • Role of IKK epsilon in KSHV/HHV8 associated malignancies
    NIH · R01DE025804 · Mar 4, 2016 – Feb 28, 2021 · Role: Principal Investigator
  • A High Throughput Protein Complementation Assay for Inhibitors of NEMO-K13 Intera
    NIH · R01CA139119 · Jul 1, 2010 – Jun 30, 2014 · Role: Principal Investigator
  • Cell Penetrating Helical Peptide Inhibitors of vFLIP K13
    NIH · R01DE019811 · Jun 1, 2010 – Mar 31, 2016 · Role: Principal Investigator
  • Small Molecule Inhibitors of K13-Induced NF-kB Activation
    NIH · R21NS063905 · Jun 15, 2008 – May 31, 2010 · Role: Principal Investigator
  • Role of vFLIP K13 in Bone Marrow Failure Syndrome Associated with Infection by Hu
    NIH · R21HL085189 · May 10, 2007 – Oct 30, 2009 · Role: Principal Investigator
  • Role of Arsenic Trioxide in Primary Effusion Lymphoma
    NIH · R01CA124621 · Dec 1, 2006 – Nov 30, 2012 · Role: Principal Investigator
  • Genes in X-linked Ectodermal Dysplasia Receptor
    NIH · R01DE015189 · Apr 1, 2003 – Mar 31, 2008 · Role: Principal Investigator
  • Role of orf-K13, an HHV8 Encoded vFLIP, in the Pathogenesis of AIDS-related Malig
    NIH · R01CA085177 · Jun 1, 2000 – May 31, 2012 · Role: Principal Investigator
  • CASPASE 8 AND ITS HOMOLOGS IN NF-KB AND JNK ACTIVATION
    NIH · R01AI047230 · Apr 1, 2000 – Mar 31, 2006 · Role: Principal Investigator

Publications

  • Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2026 Aug; 26(8):562-573.e1.. View in PubMed
  • Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia. J Med Cases. 2025 Mar; 16(3):102-106.. View in PubMed
  • Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia. J Med Cases. 2024 Oct; 15(10):261-266.. View in PubMed
  • Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy. Br J Haematol. 2024 Dec; 205(6):2234-2247.. View in PubMed
  • Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.. View in PubMed
  • Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study. Leuk Res. 2024 06; 141:107501.. View in PubMed
  • Post-stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib. EJHaem. 2024 Apr; 5(2):423-427.. View in PubMed
  • Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease. Front Oncol. 2024; 14:1329893.. View in PubMed
  • Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):e59-e66.e2.. View in PubMed
  • Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review. Respir Med Case Rep. 2023; 46:101922.. View in PubMed